Document Detail


Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study.
MedLine Citation:
PMID:  16417964     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: We evaluated the efficacy and tolerability of botulinum A toxin (BTX-A) intravesical injections in patients affected by painful bladder syndrome with increased urinary frequency, refractory to conventional treatment modalities. METHODS: Twelve women and two men were prospectively included in the study. Under short general anaesthesia patients were given injections of 200 U of commercially available BTX-A diluted in 20 ml 0.9% NaCl. Injections were performed submucosally in the trigone and bladder floor under cystoscopic control. Voiding chart, the Visual Analog Scale (VAS) for pain, and urodynamics were performed before treatment and 1 and 3 mo afterward. RESULTS: Overall, 12 patients (85.7%) reported subjective improvement at 1 and 3 mo follow-up. The mean VAS score was significantly reduced at 1 and 3 mo after treatment (p<0.05 for both); at the same time points daytime and nighttime urinary frequency significantly decreased (p<0.01 and p<0.05, respectively), and bladder cystometric capacity significantly increased (p<0.01). Two patients reported incomplete bladder emptying. We did not detect any systemic side effects during or after treatment. CONCLUSIONS: The results of this pilot study indicate that BTX-A intravesical injections are effective in the short-term management of painful bladder syndrome. By modulating afferent C-fiber activity within the bladder walls, BTX-A significantly improves urodynamic parameters and reduces bladder pain and urinary frequency.
Authors:
Antonella Giannantoni; Elisabetta Costantini; Savino M Di Stasi; Maria Cristina Tascini; Vittorio Bini; Massimo Porena
Related Documents :
11792954 - Appendiceal versus ileal segment for antegrade continence enema.
8709364 - The kock ileal neobladder: updated experience in 295 male patients.
10411034 - Sequential bacillus calmette-guerin and epirubicin versus bacillus calmette-guerin alon...
9705554 - Long-term results of augmentation cystoplasty.
11560384 - Value of angiographic embolisation for the control of major haemorrhage after oesophago...
17703314 - A novel approach for treatment of sacrococcygeal pilonidal sinus: less is more.
Publication Detail:
Type:  Journal Article     Date:  2006-01-04
Journal Detail:
Title:  European urology     Volume:  49     ISSN:  0302-2838     ISO Abbreviation:  Eur. Urol.     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-03-13     Completed Date:  2007-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7512719     Medline TA:  Eur Urol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  704-9     Citation Subset:  IM    
Affiliation:
Department of Urology, University of Perugia, Italy. agianton@tin.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intravesical
Aged
Botulinum Toxin Type A / administration & dosage,  therapeutic use*
Cystitis, Interstitial / drug therapy*
Female
Humans
Male
Middle Aged
Neuromuscular Agents / administration & dosage,  therapeutic use*
Pain Measurement
Pilot Projects
Prospective Studies
Statistics, Nonparametric
Treatment Outcome
Chemical
Reg. No./Substance:
0/Botulinum Toxin Type A; 0/Neuromuscular Agents
Comments/Corrections
Comment In:
Eur Urol. 2006 Apr;49(4):606-8   [PMID:  16457945 ]
Eur Urol. 2006 Apr;49(4):709   [PMID:  17605171 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prostatic infarction involving the urinary sphincter, an association with pyoderma gangrenosum.
Next Document:  Identification of novel gamete receptors that mediate sperm adhesion to the egg coat.